Skip to main content
Premium Trial:

Request an Annual Quote

GenapSys Raises $37M to Commercialize NGS Platform

NEW YORK (GenomeWeb News) –GenapSys said today that it has raised $37 million in a Series B financing round to support commercialization of its next-generation sequencing platform.

The Series B financing includes new investors Yuri Milner, Stanford StartX Fund, and other private and institutional investors.

The Redwood City, Calif.-based company is developing a next-gen sequencing system called GENIUS 110, which stands for Gene Electronic Nano-Integrated Ultra-Sensitive.

"With this financing and strong backing of our investors, we now have all the pieces in place to deliver on the commercial promise of the GENIUS System and realize a 100x improvement in cost and efficacy as compared to existing technologies on the market," Founder and CEO Hesaam Esfandypour said in a statement.

The firm plans to integrate advanced fluidics and analytical capabilities to develop a sample-to-answer platform for both DNA and RNA.

Last year, GenapSys received nearly $4 million in grant funding from the National Human Genome Research Institute to develop a low-cost electronic DNA sequencer.

As reported by sister publication In Sequence, the goal of the system is to sequence a genome at a consumables cost of $50, generate average read lengths of up to 1,000 bases, and provide a pre-assembly accuracy of more than 99.7 percent (IS 11/13/2012).

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.